"Texas Diabetes & Endocrinology, P.A. was founded in Austin by Dr. Thomas Blevins in 2001 and has grown over the years to meet the Endocrinology needs of our growing community with offices in Central Austin, South Austin and Round Rock. We are Central Texas’ experts in Diabetes, Thyroid, Osteoporosis, Weight loss and Hormonal conditions. Our philosophy is anchored in the belief that our patients come first and they are our partners. We have assembled a staff of Endocrinologists, Physician Assistants, and Clinical nurse specialists that spend as much time with you as you need to become educated about your diagnosis and learn how to fit a personalized treatment plan into your life."

During the past decade, Texas Diabetes and Endocrinology conducted 62 clinical trials. In the 10-year time frame, 62 clinical trials started and 36 clinical trials were completed, i.e. on average, 58.1% percent of trials that started reached the finish line to date. In the past 5 years, 37 clinical trials started and 25 clinical trials were completed. i.e. 67.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Diabetes and Endocrinology" #1 sponsor was "Eli Lilly and Company" with 24 trials, followed by "Medtronic Diabetes" with 6 trials sponsored, "Gan and Lee Pharmaceuticals, USA" with 3 trials sponsored, "Halozyme Therapeutics" with 3 trials sponsored and "Boehringer Ingelheim" with 3 trials sponsored. Other sponsors include 33 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Diabetes and Endocrinology" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Mylan GmbH" with 2 trials as a collaborator, "Amylin Pharmaceuticals, LLC." with 1 trials as a collaborator, "Compliance Solutions Ltd." with 1 trials as a collaborator and "Exploristics" with 1 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Texas Diabetes and Endocrinology" are "Diabetes Mellitus, Type 1" (10 trials), "Type 1 Diabetes" (10 trials), "Type 2 Diabetes" (10 trials), "Type 1 Diabetes Mellitus" (9 trials) and "Obesity" (8 trials). Many other conditions were trialed in "Texas Diabetes and Endocrinology" in a lesser frequency.

Most popular intervention types in "Texas Diabetes and Endocrinology" are "Drug" (50 trials), "Device" (18 trials), "Biological" (6 trials), "Other" (6 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (23 trials), "Insulin Degludec" (8 trials), "Tirzepatide" (6 trials), "Insulin Lispro" (5 trials) and "Insulin Glargine" (4 trials). Other intervention names were less common.

The vast majority of trials in "Texas Diabetes and Endocrinology" are 74 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Diabetes and Endocrinology". undefined are not yet recruiting, 10 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 52 completed trials in Texas Diabetes and Endocrinology, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Diabetes and Endocrinology, 2 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 16 trials that are defined as “Not Applicable".